COVID‐19 infection in CVID patients: What we know so far
Abstract Introduction In patients with common variable immunodeficiency (CVID), immunological response is compromised. Knowledge about COVID‐19 in CVID patients is sparse. We, here, synthesize current research addressing the level of threat COVID‐19 poses to CVID patients and the best‐known treatmen...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-09-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.450 |
| _version_ | 1831774765627473920 |
|---|---|
| author | Niels Weifenbach Alisha Jung Stefan Lötters |
| author_facet | Niels Weifenbach Alisha Jung Stefan Lötters |
| author_sort | Niels Weifenbach |
| collection | DOAJ |
| description | Abstract Introduction In patients with common variable immunodeficiency (CVID), immunological response is compromised. Knowledge about COVID‐19 in CVID patients is sparse. We, here, synthesize current research addressing the level of threat COVID‐19 poses to CVID patients and the best‐known treatments. Method Review of 14 publications. Results The number of CVID patients with moderate to severe (~29%) and critical infection courses (~10%), and the number of fatal cases (~13%), are increased compared to the general picture of COVID‐19 infection. However, this might be an overestimate. Systematic cohort‐wide studies are lacking, and asymptomatic or mild cases among CVID patients occur that can easily remain unnoticed. Regular immunoglobulin replacement therapy was administered in almost all patients, potentially explaining why the numbers of critical and fatal cases were not higher. In addition, the application of convalescent plasma was demonstrated to have positive effects. Conclusions COVID‐19 poses an elevated threat to CVID patients. However, only systematic studies can provide robust information on the extent of this threat. Regular immunoglobulin replacement therapy is beneficial to combat COVID‐19 in CVID patients, and best treatment after infection includes the use of convalescent plasma in addition to common medication. |
| first_indexed | 2024-12-22T09:00:18Z |
| format | Article |
| id | doaj.art-3c002a579a8d4b7f85f9f912cf45a9d0 |
| institution | Directory Open Access Journal |
| issn | 2050-4527 |
| language | English |
| last_indexed | 2024-12-22T09:00:18Z |
| publishDate | 2021-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj.art-3c002a579a8d4b7f85f9f912cf45a9d02022-12-21T18:31:44ZengWileyImmunity, Inflammation and Disease2050-45272021-09-019363263410.1002/iid3.450COVID‐19 infection in CVID patients: What we know so farNiels Weifenbach0Alisha Jung1Stefan Lötters2Trier University, FB VI, Biogeography Trier GermanyTrier University, FB VI, Biogeography Trier GermanyTrier University, FB VI, Biogeography Trier GermanyAbstract Introduction In patients with common variable immunodeficiency (CVID), immunological response is compromised. Knowledge about COVID‐19 in CVID patients is sparse. We, here, synthesize current research addressing the level of threat COVID‐19 poses to CVID patients and the best‐known treatments. Method Review of 14 publications. Results The number of CVID patients with moderate to severe (~29%) and critical infection courses (~10%), and the number of fatal cases (~13%), are increased compared to the general picture of COVID‐19 infection. However, this might be an overestimate. Systematic cohort‐wide studies are lacking, and asymptomatic or mild cases among CVID patients occur that can easily remain unnoticed. Regular immunoglobulin replacement therapy was administered in almost all patients, potentially explaining why the numbers of critical and fatal cases were not higher. In addition, the application of convalescent plasma was demonstrated to have positive effects. Conclusions COVID‐19 poses an elevated threat to CVID patients. However, only systematic studies can provide robust information on the extent of this threat. Regular immunoglobulin replacement therapy is beneficial to combat COVID‐19 in CVID patients, and best treatment after infection includes the use of convalescent plasma in addition to common medication.https://doi.org/10.1002/iid3.450common variable immunodeficiencyconvalescent plasmaimmunoglobulin replacementSARS‐CoV‐2 |
| spellingShingle | Niels Weifenbach Alisha Jung Stefan Lötters COVID‐19 infection in CVID patients: What we know so far Immunity, Inflammation and Disease common variable immunodeficiency convalescent plasma immunoglobulin replacement SARS‐CoV‐2 |
| title | COVID‐19 infection in CVID patients: What we know so far |
| title_full | COVID‐19 infection in CVID patients: What we know so far |
| title_fullStr | COVID‐19 infection in CVID patients: What we know so far |
| title_full_unstemmed | COVID‐19 infection in CVID patients: What we know so far |
| title_short | COVID‐19 infection in CVID patients: What we know so far |
| title_sort | covid 19 infection in cvid patients what we know so far |
| topic | common variable immunodeficiency convalescent plasma immunoglobulin replacement SARS‐CoV‐2 |
| url | https://doi.org/10.1002/iid3.450 |
| work_keys_str_mv | AT nielsweifenbach covid19infectionincvidpatientswhatweknowsofar AT alishajung covid19infectionincvidpatientswhatweknowsofar AT stefanlotters covid19infectionincvidpatientswhatweknowsofar |